Business Wire

NY-CONDECO

12.4.2022 14:32:04 CEST | Business Wire | Press release

Share
Condeco Launches New Marketing Campaign to Address the Greatest Cultural Shift in Business of the 21st Century

Condeco , a global leader in workspace scheduling software, is today announcing the launch of its new marketing campaign that is uniquely designed to address the immediate need for businesses to redefine the workplace and respond to the evolving expectations of their employees.

Condeco’s campaign will debut with a new film short that showcases the needs of the modern workplace and contextualizes the new wave of business culture that is turning the traditional office environment on its head. Positioned as a satirical comedy, the film short highlights the growing generational divide that has emerged out of the pandemic, and light-heartedly cements the importance of having an employer that understands and embraces employee needs.

In addition to the launch of this new film, Condeco’s new marketing campaign includes a new consumer report that supports the importance of fostering a workplace that respects the desires of its employees, with hybrid work opportunities at its core. As full-time remote work becomes a pandemic pastime, this report’s findings underscore the need for business leaders to prioritize employee happiness, mental health, and digital technology as they adopt hybrid work models.

“It’s no secret that there has been a seismic shift in how we work” said Lynda Lowe, CMO at Condeco. “Work is now an outcome that is no longer defined by a single physical location and there is a growing tension point between business leaders who are trying to force a return to the office and their employees who want to be able to work flexibly. But this does not mean that leaders should discount the value of the office altogether. Instead, leaders must understand the value of the office has shifted to providing a safe space for employee collaboration. The past two years have taught us that empowering employees with time and space to do this at their choosing is key to supporting their mental health and well-being, as well as driving enhanced business culture and social interaction.”

Condeco’s new marketing campaign follows the brand’s repositioning in 2021 , which recognized the immediate need for employers to provide their employees with the flexibility to work from anywhere. Delivering on its mission to help businesses redefine their workplace, Condeco acquired ProxyClick in January 2022 to expand Condeco’s workspace solutions for the enterprise, enabling the company to drive an end-to-end employee and guest experience with the connected office – and ultimately, help businesses prepare for the future at work.

Condeco’s new film will air across connected TV and social channels starting on Tuesday, April 12, 2022. Media planned and bought by Hubble , part of What’s Possible Group. The film was produced by Arts & Sciences and directed by Casey Storm, who is known for his work with brands including Paypal, Apple, Hulu, Expedia, and more.

To view the full broadcast, please see here: https://youtu.be/HunkSOvLJ4M . To learn more about Condeco’s new report on hybrid work, please see here .

About Condeco

Condeco is the global leader in enterprise level workspace solutions. Our software is designed to equip everyone with the tools they need for a seamless end to end experience in today’s office. By giving people control over flexible work, we deliver the certainty people need, enable the collaboration teams crave, and facilitate the insights on capacity that employers demand. From visitor management to workspace booking to office optimization, we are trusted by over 2000 of the world’s largest companies to realize their future at work.

About Arts & Sciences

Arts & Sciences was started over a decade ago as a boutique production company that specializes in producing award-winning advertising content, music videos, fine art projects, original documentaries, and feature films. Located in Los Angeles, NYC, and London, Arts & Sciences represents a diverse group of top directors and creators and has been named a Creativity A-List Production Company five times. Every major advertising award show has recognized its work, including Cannes Lions, Clio, AICP, D&AD, The One Show, and the Andys. Their original content work has been featured in the New Frontiers showcase at the Sundance Film Festival, The New Yorker, Nowness, and Purple Magazine. Arts & Sciences has produced work for every major global brand, such as Google, Apple, Facebook, Nike, AT&T, Samsung, Volkswagen, Ford, Toyota, American Express, MLB, the NFL, and more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye